



LANXESS – Q3 2016 results Moving forward – strategically and operationally

Matthias Zachert, CEO Michael Pontzen, CFO



Safe harbor statement

The presentation relates to the proposed acquisition of Chemtura Corp. by LANXESS AG. The information included in this presentation is being provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an an offer to purchase, securities of LANXESS AG, nor a solicitation of any vote or approval. No public market exists for the securities of LANXESS AG in the United States. This presentation contains certain forward-looking statements, including assumptions, opinions and views of the company or cited from third party

This presentation contains certain forward-looking statements, including assumptions, opinions and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document. Important Additional Information

This communication may be deemed to be solicitation material in respect of the proposed acquisition of Chemtura Corp. by LANXESS AG. The proposed acquisition will be submitted to the stockholders of Chemtura Corp. for their consideration. In connection therewith, on November 4, 2016, Chemtura Corp. filed a preliminary proxy statement with the U.S. Securities and Exchange Commission ("SEC"). Chemtura Corp. intends to file a definitive proxy statement and mail such proxy statement to its stockholders of record. BEFORE MAKING ANY VOTING OR ANY INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and stockholders will be able to obtain free copies of the proxy statement, any amendments or supplements thereto and other documents containing important information about Chemtura Corp., once such documents are filed with the SEC, through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by Chemtura Corp. will be available free of charge on Chemtura Corp.'s website at http://investor.chemtura.com under the heading "Financials & Filings". Stockholders of Chemtura Corp. may also obtain a free copy of the definitive proxy statement by contacting Chemtura Corp.'s Investor Relations Department at (203) 573-2153.



Agenda

- Executive summary Q3 2016 and outlook
- Business and financial details Q3/9M 2016
- Back-up

LANXESS

Q3 2016: Key business highlights


Strong business performance

- Higher volumes across all segments
- Acquisition of Chemours' Clean & Disinfect business successfully closed (August 31, 2016); integration ongoing
- Planned acquisition of Chemtura announced in September with closing expected mid-2017
- Realignment (phase 2) progressing ahead of plan
- Some rubber types with negative price/input cost balance due to persistent competitive price pressure
- Agro chemicals remain soft






Q3 2016: Financial performance driven by New LANXESS



LANXESS

Sustainability and quality remain in focus



Climate A List: An "A" score is given to companies that particularly distinguish themselves with regard to the transparency and completeness of their reporting and to their actual climate protection activities.




Q3 2016 financial overview: Delivering a strong quarter

€ m]	Q3 2015	Q3 2016	yoy in %	 Lower sales as higher
Sales	1,953	1,921	-1.6%	volumes offset by lower
EBITDA pre	235	257	9.4%	selling prices (raw materia price pass-through)
margin	12.0%	13.4%		 EBITDA increases with high
EPS	0.45	0.68	51.2%	volumes and an improved
EPS pre*	0.57	0.78	36.8%	cost base (better utilization
Сарех	100	106	6.0%	and savings)
[€ m]	31.12.2015	30.09.2016	Δ%	 Net financial debt on low le despite ~€200 m cash out
Net financial debt**	1,211	203	-83.2%	acquisition of Chemours' C Net working capital above
Net working capital	1,526	1,752	14.8%	year-end level (typical seasonality)
ROCE	8.4%	8.2%		oodoonanty)

net of exceptionals, using the local tax rate applicable where the expenses were incurred * after deduction of current financial assets



Q3 2016: Strong volume growth and EBITDA contribution from New LANXESS segments



LANXESS


Guidance lifted on the back of good year-to-date performance

Updated: FY 2016 EBITDA pre now expected to be between €960 m – €1,000 m

- Good underlying business across the segments year-to-date
- Realignment progressing well with some accelerated savings

Considerations for Q4 2016: normal seasonal pattern, however some additional headwinds

- Advanced Intermediates with unusual strong prior-year base and agro business generally weaker this year (esp. for BU SGO in Q4 2016)
- Automobile weaker in Europe and US
- Continuing margin pressure in EPDM: competitive price pressure with rising raw material prices
- Suppliers' outages (Singapore and Europe) burden




LANXESS

Agenda

- Executive summary Q3 2016 and outlook
- Business and financial details Q3/9M 2016
- Back-up




Q3 2016: Volume-driven earnings growth mitigated by margin pressure in ARLANXEO



LANXESS

Q3 2016: Strong Asia/Pacific demand compensates for raw



* Currency and portfolio adjusted

LANXESS


Q3 2016: Earnings growth reflects transformation towards New LANXESS

[€ m]	Q3 2	015	Q3 2	2016	yoy in %	
Sales	1,953	(100%)	1,921	(100%)	-2%	 Lower sales as higher volumes
Cost of sales	-1,498	(77%)	-1,475	(77%)	2%	are offset by pass-through of
Selling	-190	(10%)	-192	(10%)	-1%	lower raw material costs
G&A	-70	(4%)	-67	(3%)	4%	 Improved utilization across all segments and accelerated
R&D	-32	(2%)	-34	(2%)	-6%	savings compensates for
EBIT	104	(5%)	122	(6%)	17%	price/cost squeeze in ARLANXEO
Non-controlling interests	0		-2	(0%)	<-100%	SG&A under control
Net Income	41	(2%)	62	(3%)	51%	EBITDA improves on good
EPS pre	0.57		0.78		37%	volumes and more efficient cost
EBITDA	218	(11%)	241	(13%)	11%	base
thereof exceptionals	-17	(1%)	-16	(1%)	6%	
EBITDA pre exceptionals	235 ((12.0%)	257	(13.4%)	9%	
			A good se	t of num	bers	

LANXESS

13


Q3 2016: New LANXESS segments contribute to EBITDA improvement



Total group sales including reconciliation




Advanced Intermediates: Stable sales and higher earnings on improved utilization



LANXESS


15

Performance Chemicals: Stability at attractive profitability





High Performance Materials: Earnings step change due to improved product mix and favorable markets




^{*} Includes exceptional income from disposal of spare infrastructure

17



ARLANXEO: A decent quarter in a persistently challenging market





Q3 2016: Another quarter with improved cash generation

[€ m]	Q3 2015	Q3 2016				
Profit before tax	68	100	Operating cash flow improved in			
Depreciation & amortization	114	119	line with earnings improvement – free cash flow covered Chemours			
Financial (gains) losses	17	9	C&D acquisition			
Cash tax payments/refunds	-47	-37	Change in other assets and			
Changes in other assets and liabilities	76	91	liabilities reflects amongst others provisions for variable			
Operating cash flow before changes in WC	228	282	compensation			
Changes in working capital	-38	22	 Working capital reduction driven by lower receivables and higher 			
Operating cash flow	190	304	payables			
Investing cash flow	46	-170	Net cash outflow (~€200 m) for			
Thereof capex	-100	-106	Chemours' C&D business reflected in investing cash flow			
Thereof Chemours' C&D acquisition	0	-198	Financing cash flow reflects			
Financing cash flow	-75	-264	€200 m repayment of bond			



Balance sheet - Strong and ready to carry planned Chemtura acquisition

[€ m]	Dec 2015	Sept 2016	 Total assets higher with €1.2 be
Total assets	7,219	8,242	cash-in for 50% ARLANXEO and respective increase in
Equity (incl. non-controlling interest)	2,323	3,453	equity for non-controlling
Equity ratio	32%	42%	interest (April 1, 2016) ⁴
Net financial debt (after deduction of current financial assets)	1,211	203	 Pension provision up mainly or lower discount rates in German
Near cash, cash & cash equivalents	466	523	(1.5% from 3.0% year end '15)
Pension provisions	1,215	1,479	 Rock solid balance sheet with
			very low net financial debt
ROCE ¹	8.4%	8.2%	 ROCE technically lower after
Net working capital	1,526	1,752	balance sheet extension from
DSI (in days) ²	67	65	ARLANXEO cash-in ⁴
DSO (in days) ³	48	51	 DSO increase reflects strong business activity in Q3 vs year end 2015

¹ Based on last twelve months for EBIT pre ² Days sales of inventory calculated from quarterly sales 20 ³ Days of sales outstanding calculated from quarterly sales

⁴ On April 1, 2016, LANXESS placed 50% of its rubber business in a joint venture with Saudi Aramco, receiving in return ~€1.2 bn in cash



19

Balance sheet extended due to ARLANXEO effects

[€ m]	Dec'15	Sep'16		Dec'15	Sep'16
Non-current assets	4,180	4,400	Stockholders' equity	2,323	3,453
Intangible assets	300	481	attrib. to non-contr. interests	13	1,124
Property, plant & equipment	3,447	3,339	Non-current liabilities	2,936	3,218
Equity investments	0	0	Pension & post empl. provis.	1,215	1,479
Other investments	12	11	Other provisions	271	279
Other financial assets	21	19	Other financial liabilities	1,258	1,256
Deferred taxes	361	510	Tax liabilities	19	16
Other non-current assets	39	40	Other liabilities	127	104
			Deferred taxes	46	84
Current assets	3,039	3,842			
Inventories	1,349	1,395	Current liabilities	1,960	1,571
Trade accounts receivable	956	1,084	Other provisions	411	467
Other current financial assets	4	589	Other financial liabilities	443	78
Other current assets	264	251	Trade accounts payable	779	727
Near cash assets	100	2	Tax liabilities	85	138
Cash and cash equivalents	366	521	Other liabilities	242	161
Total assets	7,219	8.242	Total equity & liabilities	7,219	8,242

^{■ €1.2} bn cash received from Saudi Aramco for 50% in ARLANXEO JV, mainly allocated to current financial assets as well as cash and cash equivalents; equity increased respectively with non-controlling interest of Saudi Aramco in ARLANXEO JV



21

9M 2016 financial overview: Realignment proving results

[€ m]	9M 2015	9M 2016	yoy in %
Sales	6,096	5,784	-5.1%
EBITDA pre	734	812	10.6%
margin	12.0%	14.0%	
EPS	1.64	2.08	26.7%
EPS pre ¹	1.97	2.28	15.7%
Capex	229	228	-0.4%
[€ m]	31.12.2015	30.09.2016	yoy in %
Net financial debt ²	1,211	203	-83.2%
Net working capital	1,526	1,752	14.8%
ROCE	8.4%	8.2%	

- Lower sales due to raw material cost pass-through; partly compensated by higher volumes
- EBITDA increases on higher volumes, streamlined costs and positive FX³
- EPS increase driven by business improvement
- Net financial debt significantly reduced after ARLANXEO closing
- ROCE technically lower due to balance sheet extension




Financial liabilities down mainly due to €200 m bond repayment in September '16 (5.5% coupon)

 $^{^{\}rm 1}$ Net of exceptionals, using the local tax rate applicable where the expenses were incurred $^{\rm 2}$ After deduction of current financial assets

² After deduction of current financial assets

22 Sower hedging expenses and favorable emerging markets' currencies

9M 2016: Good volume growth in all segments




*Lower hedging expenses and favorable emerging markets' currencies

23



9M 2016: Lower sales as raw material price pass-through outpaces volume growth




* Currency and portfolio adjusted

LANXESS

24

9M 2016: Recovering earnings power



Total group sales include reconciliation

25

LANXESS

9M 2016: Realignment and underlying good business performance drive earnings

[€ m]	9M 2	015	9M 2	016	yoy in %	
Sales	6,096	(100%)	5,784	(100%)	-5%	Cost of sales decrease
Cost of sales	-4,713	(77%)	-4,400	(76%)	7%	disproportionately to sales
Selling	-573	(9%)	-577	(10%)	-1%	mainly due to lower idle costs, absence of ramp-up costs
G&A	-202	(3%)	-212	(4%)	-5%	(~€25 m in Q1'15) and savings
R&D	-98	(2%)	-96	(2%)	2%	 G&A influenced amongst other
EBIT	344	(6%)	429	(7%)	25%	by dissynergies from
Non-controlling interests	-1	(0)	6	(0%)	>100%	ARLANXEO
Net Income	150	(2%)	190	(3%)	27%	 Net income and EPS pre increase on visible business
EPS pre	1.97		2.28		16%	improvement despite deduction
EBITDA	692	(11%)	783	(14%)	13%	of non-controlling interests
thereof exceptionals	-42	(1%)	-29	(1%)	31%	
EBITDA pre exceptionals	734	(12.0%)	812 ((14.0%)	11%	



9M 2016: Continued strong cash flow conversion

[€ m]	9M 2015	9M 2016	
Profit before tax	246	341	 Swing in changes in other assets
Depreciation & amortization	348	354	and liabilities driven by effects
Gain from sale of assets	-42	0	from hedging of intercompany
Financial (gains) losses	49	42	financing and less restructuring
Cash tax payments/refunds	-70	-98	 Investing cash flow reflects: Investment in financial assets
Changes in other assets and liabilities	-28	96	from funds received due to
Operating cash flow before changes in WC	503	735	ARLANXEO closing**
Changes in working capital	-161	-203	▶ €200 m funding for German
Operating cash flow	342	532	pension assets (CTA)
Investing cash flow	-166	-1,095	~€200 m for Chemours' C&D acquisition
Thereof capex	-229	-228	Financing cash flow reflects cash-
Thereof cash inflows from/cash outflows for financial assets	14	-481	in for 50% ARLANXEO share
Thereof CTA* funding & Chemours C&D acquisitition	0	-398	(~€1.2 bn) and repayment of
Financing cash flow	-232	714	several financial liabilities


LANXESS

Agenda

- Executive summary Q3 2016 and outlook
- Business and financial details Q3/9M 2016
- Back-up



^{*} CTA: Contractual Trust Arrangement
** Closing of ARLANXEO on April 1, 2016, leading to cash-in of ~€1.2 bn




Housekeeping items


Additional financial expectations Capex 2016: ~€450 m (thereof ~€150 m ARLANXEO) Operational D&A 2016: ~€460 m (thereof ~€220 m ARLANXEO) Reconciliation 2016: underlying exp. of ~-€150 m EBITDA pre Hedging exp. now expected ~-€70 m (hedging guidance adjusted: additional relief in Recon from hedging is balanced by FX burden in operations) Annual tax rate: - 2016: around 2015 level - mid-term: 30-35% (for New LANXESS)



LANXESS: Moving strategically into more resilient, less volatile businesses




The New LANXESS: Diversified end markets and less exposure to cyclical businesses






A lean business organization



Acquisition of Chemtura: Establishing a major global additives player





Sales and EBITDA are based on Q2 2016 LTM, USD/EUR 1.10




A well managed and conservative maturity profile

Long term financing secured Liquidity and maturity profile as per September 2016* [€ m] Diversified financing sources - Bonds & private placements 750 500 - Syndicated credit facility 250 Average interest rate of financial liabilities < 2.5% -250 -500 All group financing executed -750 facility €1.25 br without financial covenants -1000 Financing of Chemtura -1250 acquisition secured with cash -1500 -1750 on balance sheet and an initial bridge loan facility of €2.0 bn -2000 2016 2023+ 2017 2018 2020 2021 2022 €1.0 bn of bonds issued with settlement on October 7, 2016 Financial liabilities ■ Cash & cash equivalents ■ Current financial assets ■ Credit facility

35



High volatility in raw material prices



^{*} Source: LANXESS, average 2013 = 100%



^{*} Bonds due in 2021 and 2026 were issued beginning of October 2016

Overview exceptional items Q3 and YTD

Q3 :	2015	Q3 2	2016	9M 2	015	9M	2016
Ехсер.	Thereof D&A	Ехсер.	Thereof D&A	Excep.	Thereof D&A	Excep.	Thereof D&A
0	0	0	0	1	0	0	0
0	0	0	0	8	0	0	0
0	0	0	0	-19	1	0	0
2	0	0	0	24	10	0	0
15	0	16	0	39	0	29	0
17	0	16	0	53	11	29	0
	0 0 0 2 15	D&A 0 0 0 0 0 0 2 0 15 0	Excep. Thereof D&A Excep. 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 15 0 16	Excep. Thereof D&A Excep. Thereof D&A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 15 0 16 0	Excep. Thereof D&A Excep. Thereof D&A Excep. 0 0 0 0 1 0 0 0 0 8 0 0 0 0 -19 2 0 0 0 24 15 0 16 0 39	Excep. Thereof D&A Excep. Thereof D&A Excep. Thereof D&A 0 0 0 0 1 0 0 0 0 0 8 0 0 0 0 -19 1 2 0 0 0 24 10 15 0 16 0 39 0	Excep. Thereof D&A Excep. Thereof D&A Excep. Thereof D&A Excep. Excep.

LANXESS

37

Abbreviations

	ARLANXEO		Performance Chemicals
• TSR • HPE	Tire & Specialty Rubbers High Performance Elastomers	ADDIPGLEAMPPLPT	Rhein Chemie Additives Inorganic Pigments Leather Material Protection Products Liquid Purification Technologies
	Advanced Intermediates		High Performance Materials
• All • SGO	Advanced Industrial Intermediates Saltigo	• HPM	High Performance Materials



Upcoming events 2016 / 2017

	 Morgan Stanley Global Chemical Conference 	November 15	Boston
16	 UBS European Conference 2016 	November 15/16	London
2016	 Deutsche Börse Eigenkapital Forum 	November 22	Frankfurt
	 HSBC Zurich Conference 	November 29	Zurich
	Oddo Forum	January 5/6	Lyon
	 Commerzbank German Investment Seminar 	January 10/11	New York
	 Unicredit/KeplerCheuvreux 16th German Corporate Conference 	January 16-18	Frankfurt
	 Bankhaus Lampe Conference 	February 2	London
2017	 HSBC SRI Conference 	February 7	Frankfurt
7	FY results 2016	March 16	
	• Q1 results 2017	May 11	
	Annual General Meeting	May 26	Cologne
	• Q2 results 2017	August 10	
	 Q3 results 2017 	November 9	

LANXESS

39

Contact details Investor Relations

